Indications for EXTAVIA:
Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Pre-medicate with analgesics and/or antipyretics on treatment days to ameliorate flu-like symptoms. Rotate inj sites. ≥18yrs: initially 0.0625mg SC every other day; increase by 25% every 2 weeks to target dose of 0.25mg SC every other day.
<18yrs: not established.
Monitor for signs/symptoms of hepatic injury; consider discontinuing if elevated transaminase levels or jaundice occurs. Depression. Suicidal ideation. Pre-existing CHF: monitor for worsening cardiac function at initiation and during treatment. Myelosuppression. Discontinue if thrombotic microangiopathy or signs/symptoms of drug-induced lupus erythematosus occurs. Monitor CBCs, differential, platelets, chemistries, liver function (at 1, 3, and 6 months then periodically). Latex allergy (diluent). Pregnancy. Nursing mothers.
Risk of hepatic injury with concomitant hepatotoxic drugs or other products (eg, alcohol).
Inj site reactions, lymphopenia, flu-like symptoms, myalgia, leukopenia, neutropenia, increased liver enzymes, headache, hypertonia, pain, rash, insomnia, abdominal pain, asthenia; inj site necrosis (suspend therapy if multiple lesions occur); rare: hepatic injury, anaphylaxis (discontinue if occurs), possibly seizures.
Single-use vials—15 (w. prefilled diluent syringe, supplies)